158 related articles for article (PubMed ID: 37062304)
1. Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial.
Temple B; Tran HP; Dai VTT; Smith-Vaughan H; ; Licciardi PV; Satzke C; Nguyen TV; Mulholland K
Lancet Infect Dis; 2023 Aug; 23(8):933-944. PubMed ID: 37062304
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial.
Licciardi PV; Temple B; Dai VTT; Toan NT; Uyen D; Nguyen CD; Phan TV; Bright K; Marimla RA; Balloch A; Huu TN; Mulholland K
Lancet Infect Dis; 2021 Oct; 21(10):1415-1428. PubMed ID: 34171233
[TBL] [Abstract][Full Text] [Related]
4. Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam.
Temple B; Nation ML; Dai VTT; Beissbarth J; Bright K; Dunne EM; Hinds J; Hoan PT; Lai J; Nguyen CD; Ortika BD; Phan TV; Thuy HNL; Toan NT; Uyen DY; Satzke C; Smith-Vaughan H; Huu TN; Mulholland K
Vaccine; 2021 Apr; 39(16):2303-2310. PubMed ID: 33745731
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
6. Simplified 0+1 and 1+1 pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam: protocol for a randomised controlled trial.
Temple B; Tran HP; Dai VTT; Bright K; Uyen DY; Balloch A; Licciardi P; Nguyen CD; Satzke C; Smith-Vaughan H; Nguyen TV; Mulholland K
BMJ Open; 2021 Nov; 11(11):e056505. PubMed ID: 34845082
[TBL] [Abstract][Full Text] [Related]
7. Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix
Kawade A; Dayma G; Apte A; Telang N; Satpute M; Pearce E; Roalfe L; Patil R; Wang Y; Noori N; Gondhali A; Juvekar S; Oron AP; Sanghavi S; Goldblatt D; Dagan R; Bavdekar A
Vaccine; 2023 May; 41(19):3066-3079. PubMed ID: 37045679
[TBL] [Abstract][Full Text] [Related]
8. Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trial.
Smith-Vaughan H; Temple B; Trang Dai VT; Hoan PT; Loc Thuy HN; Phan TV; Bright K; Toan NT; Uyen DY; Nguyen CD; Beissbarth J; Ortika BD; Nation ML; Dunne EM; Hinds J; Lai J; Satzke C; Huu TN; Mulholland K
Lancet Reg Health West Pac; 2023 Mar; 32():100651. PubMed ID: 36785850
[TBL] [Abstract][Full Text] [Related]
9. Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial.
Olwagen CP; Izu A; Mutsaerts EAML; Jose L; Koen A; Downs SL; Van Der Merwe L; Laubscher M; Nana AJ; Moultrie A; Cutland CL; Dorfman JR; Madhi SA
Lancet Child Adolesc Health; 2023 May; 7(5):326-335. PubMed ID: 36934731
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.
Goldblatt D; Southern J; Andrews NJ; Burbidge P; Partington J; Roalfe L; Valente Pinto M; Thalasselis V; Plested E; Richardson H; Snape MD; Miller E
Lancet Infect Dis; 2018 Feb; 18(2):171-179. PubMed ID: 29174323
[TBL] [Abstract][Full Text] [Related]
13. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys.
Dunne EM; Satzke C; Ratu FT; Neal EFG; Boelsen LK; Matanitobua S; Pell CL; Nation ML; Ortika BD; Reyburn R; Jenkins K; Nguyen C; Gould K; Hinds J; Tikoduadua L; Kado J; Rafai E; Kama M; Mulholland EK; Russell FM
Lancet Glob Health; 2018 Dec; 6(12):e1375-e1385. PubMed ID: 30420033
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial.
Kandasamy R; Gurung M; Thorson S; Yu LM; Galal U; Voysey M; Kelly S; Wahl B; Berbers G; Finnegan K; Ansari I; Paudel K; Murdoch DR; O'Brien KL; Kelly DF; Goldblatt D; Shrestha S; Pollard AJ
Lancet Infect Dis; 2019 Feb; 19(2):156-164. PubMed ID: 30635252
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial.
Orami T; Aho C; Ford RL; Pomat WS; Greenhill A; Kirkham LA; Masiria G; Nivio B; Britton KJ; Jacoby P; Richmond PC; van den Biggelaar AHJ; Lehmann D
Vaccine; 2023 Aug; 41(37):5392-5399. PubMed ID: 37479616
[TBL] [Abstract][Full Text] [Related]
16. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
[TBL] [Abstract][Full Text] [Related]
17. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Shrestha S; Gurung M; Amatya P; Bijukchhe S; Bose AS; Carter MJ; Gautam MC; Gurung S; Hinds J; Kandasamy R; Kelly S; Khadka B; Maskey P; Mujadidi YF; O'Reilly PJ; Pokhrel B; Pradhan R; Shah GP; Shrestha S; Wahl B; O'Brien KL; Knoll MD; Murdoch DR; Kelly DF; Thorson S; Voysey M; Pollard AJ;
Lancet Glob Health; 2022 Oct; 10(10):e1494-e1504. PubMed ID: 36113533
[TBL] [Abstract][Full Text] [Related]
18. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.
Hamaluba M; Kandasamy R; Upreti SR; Subedi GR; Shrestha S; Bhattarai S; Gurung M; Pradhan R; Voysey M; Gurung S; Pradhan S; Thapa AK; Maharjan R; Kiran U; Kerridge SA; Hinds J; van der Klis F; Snape MD; Murdoch DR; Kelly S; Kelly DF; Adhikari N; Thorson S; Pollard AJ
Lancet Infect Dis; 2015 Apr; 15(4):405-14. PubMed ID: 25701560
[TBL] [Abstract][Full Text] [Related]
20. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
